Recombinant SARS-CoV-2 B.1.617.2 Spike His-tag Protein, CF

Name: Recombinant SARS-CoV-2 B.1.617.2 Spike His-tag Protein, CF
Brand: R&D Systems
SKU: 10942-CV

R&D Systems, Inc. a Bio-Techne Brand

Catalog # 10942-CV

Citations (1)

Product Datasheet / COA / SDS

L452R T478K Delta Variant (India)

Catalog #

Availability

Size / Price

Qty

Setting the standard in quality research reagents

Key Product Details

Source:	HEK293
Accession #:	YP_009724390.1
Applications:	Bioactivity

View Full Technical Details for Recombinant SARS-CoV-2 B.1.617.2 Spike His-tag Protein, CF

Product Specifications for Recombinant SARS-CoV-2 B.1.617.2 Spike His-tag Protein, CF

Source	Human embryonic kidney cell, HEK293-derived sars-cov-2 Spike protein Val16-Lys1211 (Thr19Arg, Gly142Asp, Glu156Gly, Phe157 del, Arg158 del, Leu452Arg, Thr478Lys, Asp614Gly, Pro681Arg, Asp950Asn) (Arg682Ser, Arg685Ser, Lys986Pro, Val987Pro), with a C-terminal 6-His tag
Purity	>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin level	<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal sequence Analysis	Val16
Predicted Molecular Mass	134 kDa
SDS-PAGE	150-165 kDa, reducing conditions.
Activity	Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 His-tag (Catalog # 933-ZN).

Scientific Data Examples for Recombinant SARS-CoV-2 B.1.617.2 Spike His-tag Protein, CF

	Recombinant SARS-CoV-2 B.1.617.2 Spike His-tag Protein Binding Activity. Recombinant SARS-CoV-2 B.1.617.2 Spike L452R T478K His-tag (Catalog # 10942-CV) binds Recombinant Human ACE-2 His-tag (933-ZN) in a functional ELISA.
	Recombinant SARS-CoV-2 B.1.617.2 Spike His-tag Protein SDS-PAGE. 2 μg/lane of Recombinant SARS-CoV-2 B.1.617.2 Spike His-tag Protein (Catalog # 10942-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized byCoomassie® Blue staining, showing bands at 150-165 kDa.

Formulation, Preparation and Storage

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

10942-CV

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: Spike

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that also include MERS-CoV and SARS-CoV-1. Coronaviruses are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M) and Nucleocapsid protein (N) (1). The SARS-CoV-2 S protein is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). The S protein of SARS‑CoV‑2 shares 75% and 29% amino acid sequence identity with S protein of SARS-CoV-1 and MERS, respectively. The S Protein of the SARS-CoV-2 virus, like the SARS-CoV-1 counterpart, binds a metallopeptidase, Angiotensin-Converting Enzyme 2 (ACE-2), but with much higher affinity and faster binding kinetics through the receptor binding domain (RBD) located in the C-terminal region of S1 subunit (6). It has been demonstrated that the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (7, 8). Polyclonal antibodies to the RBD of the SARS-CoV-2 protein have been shown to inhibit interaction with the ACE-2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy (9). There is also promising work showing that the RBD may be used to detect presence of neutralizing antibodies present in a patient's bloodstream, consistent with developed immunity after exposure to the SARS-CoV-2 (10). Several emerging SARS-CoV-2 genomes have been identified with mutations in the RBD compared to the Wuhan-Hu-1 SARS-CoV-2 reference sequence. First detected in India in December 2020, the B.1.617.2, or Delta variant, is considered a Variant of Concern (VOC) as it contains several mutations that potentially affect viral fitness and transmissibility. The L452R mutation is located in the RBD and is known to increase affinity for ACE-2 receptors and is associated with resistance to neutralization by multiple monoclonal antibodies (11, 12). Also located in the RBD, the T478K mutation shows significant increase in ACE-2 binding affinity and may make the variant more transmissible and infectious (13). The D614G mutation is located nearby to the RBD domain and has been shown to increase viral infectivity (14). The P618H mutation is found adjacent to the furin cleavage site and is proposed to enhance S protein cleavage and increase viral infectivity (15). Additionally, vaccines developed against SARS-CoV-2 show a decrease in efficacy towards the Delta variant (16).

Item	Value
References	Wu, F. et al. (2020) Nature 579:265. Tortorici, M.A. and D. Veesler (2019) Adv. Virus Res. 105:93. Bosch, B.J. et al. (2003). J. Virol. 77:8801. Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. 106:5871. Millet, J.K. and G.R. Whittaker (2015) Virus Res. 202:120. Ortega, J.T. et al. (2020) EXCLI J. 19:410. Wang, K. et al. (2020) bioRxiv https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1. Isabel, et al. (2020) Sci. Rep. 10, 14031. https://doi.org/10.1038/s41598-020-70827-z. Tai, W. et al. (2020) Cell. Mol. Immunol. https://doi.org/10.1016/j.it.2020.03.007.1. Okba, N.M.A. et al. (2020). Emerg. Infect. Dis. https://doi.org/10.3201/eid2607.200841. Liu, Z. et al. (2021) Cell Host Microbe. 29:477. Motozono, C. et al. (2021) bioRxiv, https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1. Wang, R. et al. (2021) Genomics 113:2158. Zhang, L. et al. (2020) Nat Commun. 11:6013. Lasek-Nesselquist, E. et al. (2021) medRxiv https://doi.org/10.1101/2021.03.10.21253285. Pouwels, K.B. et al. (2021) Preprint at Univ. Oxford https://www.ndm.ox.ac.uk/files/coronavirus/covid-19-infection-survey/finalfinalcombinedve20210816.pdf.
Long Name	Spike Protein
Entrez Gene IDs	918758 (HCoV-229E); 2943499 (HCoV-NL63); 39105218 (HCoV-OC43); 37616432 (MERS-CoV); 1489668 (SARS-CoV); 43740568 (SARS-CoV-2)
Alternate Names	2019-nCoV S Protein, 2019-nCoV Spike, COVID-19 Spike, E2, Human coronavirus spike glycoprotein, Peplomer protein, S Protein, S glycoprotein, SARS-COV-2 S protein, SARS-COV-2 Spike glycoprotein, SARS-CoV-2, SARSCOV2 Spike protein, Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein, Spike, Spike glycoprotein, surface glycoprotein

Citations for Recombinant SARS-CoV-2 B.1.617.2 Spike His-tag Protein, CF (1)

Showing 1 - 1 of 1 citation Showing All

Filter By:

Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Recombinant SARS-CoV-2 B.1.617.2 Spike His-tag Protein, CF include:

Species: Human
Sample Types: Whole Cells
Applications: Cell Culture

C Gallen et al. (2022), Long-Term CD4+ T-Cell and Immunoglobulin G Immune Responses in Oncology Workers following COVID-19 Vaccination: An Interim Analysis of a Prospective Cohort Study Vaccines, 10(11).
PMID: 36423026

There are no citations that match your criteria.